OverviewSuggest Edit

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain, and pruritus are managed. The Company aim to achieve this by developing new products that selectively target the body’s peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics.

TypePublic
Founded2004
HQStamford, US
Websitecaratherapeutics.com

Latest Updates

Employees (est.) (Feb 2019)37
Job Openings5
Revenue (FY, 2018)$13.5 M(+1379%)
Share Price (Mar 2019)$19.5 (+12%)

Key People/Management at Cara Therapeutics

Derek Chalmers

Derek Chalmers

Chief Executive Officer, President, and Director
Mani Mohindru

Mani Mohindru

Chief Financial Officer and Chief Strategy Officer
Michael E. Lewis

Michael E. Lewis

Chief Scientific Advisor
Frédérique Menzaghi

Frédérique Menzaghi

Senior Vice President Research and Development
Joseph Stauffer

Joseph Stauffer

Chief Medical Officer
Eric Vandal

Eric Vandal

Vice President, Commercial Operations
Show more

Cara Therapeutics Office Locations

Cara Therapeutics has an office in Stamford
Stamford, US (HQ)
4 Stamford Ave
Show all (1)
Report incorrect company information

Cara Therapeutics Financials and Metrics

Cara Therapeutics Revenue

Cara Therapeutics's revenue was reported to be $13.47 m in FY, 2018
USD

Revenue (FY, 2018)

13.5m

Net income (FY, 2018)

(74.0m)

EBIT (FY, 2018)

(77.4m)

Market capitalization (13-Mar-2019)

768.4m

Closing stock price (13-Mar-2019)

19.5

Cash (31-Dec-2018)

15.1m
Cara Therapeutics's current market capitalization is $768.4 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

3.8m86.0k911.0k13.5m

Revenue growth, %

(98%)959%

General and administrative expense

7.8m9.2m11.9m15.3m

R&D expense

21.2m49.3m48.5m75.5m
Quarterly
USDQ2, 2014Q2, 2015Q3, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

960.0k874.0k2.4m911.0k2.9m

General and administrative expense

1.5m1.9m1.9m2.4m2.7m3.8m3.7m3.7m

R&D expense

3.2m4.7m5.6m20.8m7.0m9.2m13.4m17.0m

Operating expense total

4.7m6.6m7.4m23.2m9.6m13.0m17.1m20.7m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

15.1m12.1m9.4m15.1m

Prepaid Expenses

1.7m1.5m1.6m

Current Assets

108.9m61.4m95.1m168.1m

PP&E

1.3m1.6m1.2m880.0k
Quarterly
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

24.7m(57.3m)(58.1m)(74.0m)

Depreciation and Amortization

839.0k1.5m495.0k

Accounts Payable

5.1m

Cash From Operating Activities

(21.5m)(47.4m)(54.8m)(22.3m)
USDY, 2018

Revenue/Employee

364.0k

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Cara Therapeutics News and Updates

Cara Therapeutics to Present at November Investor Conferences

STAMFORD, Conn., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced …

Cara Therapeutics Reports Third Quarter 2018 Financial Results

– Conference call today at 4:30 p.m. ET –

Marijuana Global Market Top Key Players – Cara Therapeutics,  Cannabis Sativa,  CannaGrow Holdings , United Cannabis,  Growblox Sciences and Forecast to 2025

Wiseguyreports.Com Added New Market Research Report On -“Global Marijuana Market 2018 Top Key Players, Production , Growth and Future Demand Forecast to 2025 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Cara Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

STAMFORD, Conn., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced…

Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress

STAMFORD, Conn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced…
Show more
Report incorrect company information

Cara Therapeutics Blogs

Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Conference call today at 4:30 p.m. ET STAMFORD, Conn. , March 12, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting

Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

STAMFORD, Conn. , March 05, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today

Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus Content Import Mon, 01/07/2019 - 07:06 Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difel…

Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus Content Import Wed, 01/02/2019 - 07:06 Cara Therapeutics Announces No Modifications in Trial S…

Charles Duncan, Ph.D.

Charles Duncan, Ph.D. Brian.Hoenig@n… Fri, 09/21/2018 - 09:01 Charles Duncan, Ph.D Cantor Fitzgerald & Co.

Cara Therapeutics Frequently Asked Questions

  • When was Cara Therapeutics founded?

    Cara Therapeutics was founded in 2004.

  • Who are Cara Therapeutics key executives?

    Cara Therapeutics's key executives are Derek Chalmers, Mani Mohindru and Michael E. Lewis.

  • How many employees does Cara Therapeutics have?

    Cara Therapeutics has 37 employees.

  • What is Cara Therapeutics revenue?

    Latest Cara Therapeutics annual revenue is $13.5 m.

  • What is Cara Therapeutics revenue per employee?

    Latest Cara Therapeutics revenue per employee is $364 k.

  • Who are Cara Therapeutics competitors?

    Competitors of Cara Therapeutics include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.

  • Where is Cara Therapeutics headquarters?

    Cara Therapeutics headquarters is located at 4 Stamford Ave, Stamford.

  • Where are Cara Therapeutics offices?

    Cara Therapeutics has an office in Stamford.

  • How many offices does Cara Therapeutics have?

    Cara Therapeutics has 1 office.